Rise and shine, everyone, another busy day is on the way. Yes, indeed, the middle of the week is already here, which means there is much to do. No doubt, you can relate on some level. So please join us as we grab a cup of stimulation — remember, no prescription is required — and tackle the Zoom and Skype calls and deadlines that are piling up. Meanwhile, here is the latest grab bag of items to help you along. Hope you conquer the world today, and do stay in touch. …

The National Institutes of Health is launching studies of monoclonal antibodies in patients with mild to moderate Covid-19, CNBC tells us. The trials re part of a government-industry collaboration known as ACTIV, for Accelerating Covid-19 Therapeutic Interventions and Vaccines, and will look an experimental Eli Lilly (LLY) treatment that is being developed with AbCellera. Earlier this week, the company began a Phase 3 trial testing whether the treatment can prevent the spread of Covid-19 in nursing home residents and staff.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy